COVID-19 and HIV co-infection: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 27: | Line 27: | ||
**not on antiretroviral therapy. | **not on antiretroviral therapy. | ||
==Presentation== | |||
* There hasn't been any observable difference in clinical presentation among people with HIV infection as compared to the general population. | * There hasn't been any observable difference in clinical presentation among people with HIV infection as compared to the general population. | ||
*Common symptoms for COVID-19 are | *Common symptoms for COVID-19 are | ||
| Line 43: | Line 43: | ||
==Recommendations for Patients with HIV== | |||
*Maintain the supply for antiretroviral therapy for a minimum of 30 days. | *Maintain the supply for antiretroviral therapy for a minimum of 30 days. | ||
*Virtual visit and telemedicine should be considered for non-urgent care and non-adherence counseling | *Virtual visit and telemedicine should be considered for non-urgent care and non-adherence counseling | ||
| Line 49: | Line 49: | ||
*If they develop symptoms of COVID-19 like fever, cough, shortness of breath, etc they should seek medical advice. | *If they develop symptoms of COVID-19 like fever, cough, shortness of breath, etc they should seek medical advice. | ||
*They should make sure their vaccination status is updated. | *They should make sure their vaccination status is updated. | ||
==Screening== | ==Screening== | ||
Revision as of 17:54, 10 July 2020
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 and HIV co-infection On the Web |
|
American Roentgen Ray Society Images of COVID-19 and HIV co-infection |
|
Risk calculators and risk factors for COVID-19 and HIV co-infection |
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Harmeet Kharoud M.D.[2]
Synonyms and keywords:
Overview
- An observational prospective study found out that the incidence of HIV-infected individuals to be affected by SARS-CoV-2 was similar to the general population.
- Specific antiretroviral therapy did not affect COVID-19 severity.
- Immunosuppression(low CD4 cell counts) was associated with COVID-19 severity.
- Patients with HIV infection often have other comorbidities(lung disease, cardiovascular disease) therefore, increasing the risk for severe-COVID-19 disease.
Historical Perspective
Pathophysiology
Epidemiology and Demographics
Risk
- At present people with HIV who are at greatest risk of Severe COVID-19 infection are people -
- who have lowCD4 cell count.
- not on antiretroviral therapy.
Presentation
- There hasn't been any observable difference in clinical presentation among people with HIV infection as compared to the general population.
- Common symptoms for COVID-19 are
- Fever or chills
- Cough[1]
- Shortness of Breath or difficulty breathing
- Fatigue
- Muscle or Body aches
- Headache
- New loss of taste or smell
- Sore Throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea
Recommendations for Patients with HIV
- Maintain the supply for antiretroviral therapy for a minimum of 30 days.
- Virtual visit and telemedicine should be considered for non-urgent care and non-adherence counseling
- People with suppressed HIV viral load and in stable health, should postpone their routine medical care and laboratory visits to the extent possible.
- If they develop symptoms of COVID-19 like fever, cough, shortness of breath, etc they should seek medical advice.
- They should make sure their vaccination status is updated.